Biomarkers in Cerebrospinal Fluid in Development Alzheimer’s Disease: A Systematic Review
DOI:
https://doi.org/10.20435/pssa.v0i0.927Keywords:
Alzheimer's, biomarkers, cerebrospinal fluid, tau, amyloidAbstract
This study aimed to identify studies that analyzed the total tau (T-tau), phosphorylated tau (P-tau) and beta-amyloid (Aβ) biomarkers in the cerebrospinal fluid (CSF) to the development of Alzheimer’s disease (AD). The study is characterized as a systematic review, that was applied a search logic in PubMed, SciELO e Medline, selecting studies according to inclusion and exclusion criteria. Eight clinical studies were evaluated, and all of these found elevated levels of T-tau and P-tau and decreased levels of Aβ, but not all studies found statistical significance in these findings. The dosage of the biomarkers Aβ, T-tau, and P-tau together present a great diagnostic potential of AD; however, more studies are needed to establish cutoff values of these biomarkers in disease progression.
References
Albert, M., Zhu, Y., Moghekar, A., Mori, S., Miller, M., Soldan, A., . . . Wang M. (2018). Predicting progression from normal cognition to mild cognitive impairment for individuals at 5 years. Brain Journal, 141(3), 877-887. Disponível em https://academic.oup.com/brain/article/141/3/877/4818093
Araki, W., Hattori, K., Kanemaru, K., Yokoi, Y., Omachi, Y., Takano, H., . . . Mizusawa, H. (2017). Re-evaluation of soluble APP-α and APP-β in cerebrospinal fluid as potential biomarkers for early diagnosis of dementia disorders. Biomarker research, 5(28). Disponível em https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610422/pdf/40364_2017_Article_108.pdf
Associação Brasileira de Alzheimer. (s.d.). O que é Alzheimer? Disponível em http://abraz.org.br/web/sobre-alzheimer/o-que-e-alzheimer/
Blennow, K., Dubois, B., Fagan, A. M., Lewczuk, P., Leon, M. J, & Hampel, H. (2015). Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease. Alzheimer’s e Dementia, 11(1), 58-69. Disponível em https://www.alzheimersanddementia.com/article/S1552-5260(14)00066-1/fulltext
Choi, M., Lohman, M. C., & Mezuk, B. (2014) Trajectories of cognitive decline by driving mobility: Evidence from the Health and Retirement Study. Int J Geriatr Psychiatry, 29(5), 447-53. Disponível em https://onlinelibrary.wiley.com/doi/full/10.1002/gps.4024
Corrêa, J. D., Starling, D., Teixeira., A. L., Caramelli, P., & Silva T. A. (2011). Chemokines in CSF of Alzheimer’s disease patients. Arquivos de Neuro-Psiquiatria, 69(3), 455-459. Disponível em http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004282X2011000400009&lng=en&nrm=iso&tlng=en
De Souza, L. C., Bertoux, M., Funkiewiez, A., Samri, D., Azuar, C., Habert, . . . Dubois, B. (2013). Frontal presentation of Alzheimer’s disease: A series of patients with biological evidence by CSF biomarkers. Dementia & Neuropsychologia, 7(1), 66-74. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5619547/
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., . . . Cummings, J. L. (2014). Advancing research diagnostic criteria for Alzheimer’s disease: The IWG-2 criteria. The Lancet Neurology, 13(6), 614-29. Disponível em https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(14)70090-0/fulltext#%20
Engelhardt, E., Brucki, S. M., Cavalcanti, J. L. S., Forlenza, O. V., Laks, J., & Vale, F. A. C (2005). Tratamento da doença de Alzheimer: recomendações e sugestões do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia. Arquivos de Neuro-Psiquiatria, 63(4), 1104-1112. Disponível em http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2005000600035
Forlenza, O. V. (2005). Tratamento farmacológico da doença de Alzheimer. Archives of Clinical Psychiatry, 32(3), 137-148. Disponível em http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0101-60832005000300006
Frota, N. A. F., Nitrini, R., Damasceno, B. P., Forlenza, O., Tosta, E. D., Silva, A. B., . . . Magaldi, R. M. (2011). Critérios para o diagnóstico de doença de Alzheimer. Dementia & Neuropsychologia, 5(1), 5-10. Disponível em http://www.demneuropsy.com.br/imageBank/pdf/v5s1a02.pdf
Gordon, B. A., Friedrichsen, K., Brier, M., Blazey, T., Su, Y., Christensen, J., . . . Benzinger T. L. (2016). The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain, 139(8), 2249-2260. Disponível em https://academic.oup.com/brain/article/139/8/2249/1753889
La Joie, R., Bejanin, A., Fagan, A., Ayakta, N., Baker, S., Bourakova, . . . Rabinovici, G. D. (2018). Associations between [18F] AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology, 90(4), 282-290. Disponível em https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5798657/pdf/NEUROLOGY2017827394.pdf
Lashley, T., Schott, J., Weston, P., Murray, C. E., Wellington, H., Keshavan, A., . . . Zetterberg, H. (2018). Molecular biomarkers of Alzheimer’s disease: Progress and prospects. Disease Models & Mechanisms, 11(5), Disponível em https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992610/
Magalhães, C., Figueiró, M., Fraga, V., Mateo, E., Toledo, A., Carvalho, M. G., . . . Gomes, K. B. (2015). Cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer’s disease. Jornal Brasileiro de Patologia e Medicina Laboratorial, 51(6), 376-382. Disponível em http://www.scielo.br/pdf/jbpml/v51n6/1676-2444-jbpml-51-06-0376.pdf
Marques, A. F., & Lapa, T. A. (2018). Anestesia e doença de Alzheimer. Revista Brasileira de Anestesiologia, 68(2), 174-182. Disponível em http://www.scielo.br/pdf/rba/v68n2/pt_0034-7094-rba-68-02-0174.pdf
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., . . . Phelps, C. H. (2011). The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging and Alzheimer’s Association workgroup. Alzheimers Dement, 7(3), 263-9. Disponível em https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312024/pdf/nihms363310.pdf
Nitzsche, B. A., Moraes, H. P., & Tavares, A. R. (2015). Doença de Alzheimer: Novas diretrizes para o diagnóstico. Revista Médica de Minas Gerais, 25(2), 237-243. Disponível em https://docplayer.com.br/4407071-Doenca-de-alzheimer-novas-diretrizes-para-o-diagnostico.html
Organizacón Mundial de la Salud. (2019). Demencia. Disponível em https://www.who.int/es/news-room/fact-sheets/detail/dementia
Pan, C., Korff, A., Galasko, D., Ginghina, C., Peskind, E., Li, G., . . . Zhang, J. (2015). Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer’s Disease. Journal of Alzheimer’s Disease, 45(3), 709-19. Disponível em https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517668/
Pedroso, R. V., Corazza, D. I., Andreatto, C., da Silva, T., Costa, J., & Santos-Galduróz, R. F. (2018). Cognitive, functional and physical activity impairment in elderly with Alzheimer’s disease. Dementia & Neuropsychologia, 12(1), 28-34. Disponível em https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901246/
Piguet, O., Hornberger, M., Mioshi, E., & Hodges, J. R. (2011). Behavioural-variant frontotemporal dementia: Diagnosis, clinical staging, and management. The Lancet Neurology, 10(2), 162-172. Disponível em https://www.ncbi.nlm.nih.gov/pubmed/21147039
Radanovic, M., Stella, F., Silva, L. G., Talib, L. L., & Forlenza, O. V. (2017). Increased CSF levels of total Tau in patients with subcortical cerebrovascular pathology and cognitive impairment. Dementia & Neuropsychologia, 11(4), 419-425. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770001/
Schoonenboom, N. S., Pijnenburg, Y. A., Mulder, C., Rosso, S. M., Van Elk, E. J., Van Kamp, . . . Scheltens, P. (2004). Amyloid beta (1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology, 62(9), 1580-1584. Disponível em https://www.ncbi.nlm.nih.gov/pubmed/15136685
Sereniki, A., & Vital, M. A. (2008). A doença de Alzheimer: Aspectos fisiopatológicos e farmacológicos. Revista de Psiquiatria do Rio Grande do Sul, 30(1). Disponível em http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0101-81082008000200002
Stouta, S., Babulala, G., Maa, C., Carrd, D., Heada, D., Granta, E., . . . Roe, C. M. (2017). Driving cessation over a 24-year period: Dementia severity and cerebrospinal fluid biomarkers. Alzheimer’s & Dementia, 14(5), 610-616. Disponível em https://www.ncbi.nlm.nih.gov/pubmed/29328928
Trombetta, B. A., Carlyle, B. C., Koenig, A. M., Shaw, L. M., Trojanowski, J. Q., Wolk, D. A., . . . Arnold, S. E. (2018). The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer’s disease. PloS One, 13(3). Disponível em https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837100/
World Health Organization. (2018). The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Genebra: WHO. Disponível em https://www.who.int/classifications/icd/en/bluebook.pdf
Yew, B., Alladi, S., Shailaja, M., Hodges, J. R., & Hornberger, M. (2013). Lost and forgotten? Orientation versus memory in Alzheimer’s disease and frontotemporal dementia. Journal of Alzheimer’s Disease, 33(2), 473-481.
Published
How to Cite
Issue
Section
License
The articles published on journal Psicologia e Saúde holds the copyrights of all texts published by it. Due to that, there is a demand for a letter of copyright cession (see Appreciation). The full reproduction of any article of this Journal in other publications, by any means, requires a written authorization of the Editorial Board. Partial reproductions of articles (abstracts, more than 500 words of text, tables, pictures and other illustrations, sound files) should have the written permission of the Editorial Board and the Authors.
.jpg){kind=small}
